Introduction
Many marine algal extracts possess anticoagulant properties. About 150 species representing three major divisions of marine algae have been reported to have blood anticoagulant activities [1] with a greater incidence of anticoagulant activity in extracts from the Phaeophyta [2] .
The anticoagulant activity of brown marine algae is attributed to 'fucans', a class of sulfated fucose-rich carbohydrates, which includes fucoidin, fucoidan, ascophyllan, sargassan, and glucuronoxylofucan [2] . The most active fucoidan fractions have high fucose content and the thrombin inhibition activity of these fractions exceeds that of heparin [3] . Fucoidan activity is related to its capacity to catalyze the inhibition of thrombin by its natural inhibitors antithrombin and heparin cofactor-II [4, 5] .
Like heparin, fucoidans are not homogenous substances. The Undaria pinnatifida fucoidan is a galactofucan sulfate with an average molecular weight of approximately 713 kD. The type of linkage is L-Fucose linked 1!3 and 1!4, and C-2 or C-4 is sulfated.
The widely used naturally occurring anticoagulant heparin has several side effects such as development of thrombocytopenia [6, 7] , hemorrhagic effect [8, 9] , ineffectiveness in congenital or acquired antithrombin deficiencies, and incapacity to inhibit thrombin bound to fibrin [10, 11] . It is extracted from pig intestine or bovine lung, posing a risk of zoonoses and potential ethical issues, highlighting a need for alternative anticoagulant and antithrombotic therapies, especially ones that are orally available.
Materials and methods

Human volunteers
Twenty healthy human volunteers of either sex aged between 23 and 58 years (average 40) were chosen after advertising and meeting the study criteria. All volunteers were nonsmokers with no history of thyroid abnormalities or sulfur allergy and had not received any medication in the 30 days prior to commencing the study and had not taken food supplements, seafood, or food containing seaweed-derived products in the 7 days prior to commencing the study and during the study. Informed consent was obtained from all volunteers after human ethics approval was obtained from the Southern Tasmania Health & Medical Human Research Ethics Committee and the Royal Hobart Hospital Research Ethics Committee.
The clinical trial is a single-blinded clinical phase I/II trial using a single dose of either guar gum fiber as a placebo treatment or seaweed extract containing 75% fucoidan as an active treatment. Volunteers took 3 g of the treatment three times daily (t.i.d.) for a period of 12 days. Venous blood samples were collected from volunteers using citrate and EDTA anticoagulant-containing tubes for different tests.
Preparation of capsules
The study fucoidan is a highly sulfated, polyanionic soluble fiber derived from Tasmanian U. pinnatifida (Marinova Pty. Ltd., Hobart, Tasmania, Australia) using Maritech extraction process. It is an off-white powder containing less than 10% (w/w) moisture, 24.76% fucose, 20.35% galactose, 29.07% sulfate, 2.19% protein, no mannose and 7% bound ions. For placebo, we chose a neutral nonsulfated dietary fiber derived from guar gum (Novartis Pty. Ltd., Mulgrave, Victoria, Australia). The fucoidan and guar gum capsules were prepared as described previously [12] .
Complete blood count and plasma level of fucoidan
Complete blood counts were obtained for all volunteers before and after taking the fucoidan using an automated cell counter (CELL-DYN 4000 System; Abbott Laboratories, Santa Clara, California, USA). Fucoidan concentration in plasma was measured using the 1B1 antibody, raised against sulfated polysaccharides, according to the competitive enzyme-linked immunosorbent assay (ELISA) method that was described previously [12] .
In-vitro experiments
For the in-vitro study, 1 g of 75% fucoidan extract was dissolved in 10 ml pooled normal plasma (PNP) to prepare a stock solution at 100 000 mg/l. Then the fucoidan stock solution was diluted with PNP to make serial dilutions ranging from 0 to 50 000 mg/l.
Coagulation tests
All tests were performed on the Sysmex CA6000 (Sysmex Corporation, Kobe, Japan) automated instrument using citrated plasma samples. According to the manufacturer's specifications (Dade Behring, Marburg, Germany), the following tests were performed. The activated partial thromboplastin time (aPTT) was determined using Dade Actin FSL activated PTT reagent. The antithrombin-III (AT-III) was determined using Berichrom Antithrombin-III (A). The thrombin time was determined using thromboclotin assay kit. Antifactor-Xa (anti-Xa) was determined using spectrolyse heparin (Xa) (Trinity Biotech plc, Bray, County Wicklow, Ireland). The prothrombin time (PT) was quantitatively determined using RecombiPlasTin (Instrumentation Laboratory Company, Lexington, Massachusetts, USA).
Statistical analysis
The fucoidan standard curve was constructed using mean and SD. To calculate the fucoidan concentration in the plasma, triplicate readings were averaged and subtracted from the average blank readings. Statistical parameters were calculated using Microsoft Office Excel (Microsoft, Redmond, Washington, USA) and SPSS (SPSS Inc., Chicago, Illinois, USA).
Results
In-vitro hemostasis activity of fucoidan It was observed that 75% fucoidan has a very strong hemostasis effect (Table 1 ). It prolonged the aPTT time from 30.8 s for control to 172.5 s at 63 mg/l. There was no detectable clot formation for concentrations higher than 100 mg/l. The thrombin time was also prolonged but at a higher rate in which it was 15.2 s at baseline and went up to 240.1 s at 15.6 mg/l and then no clot was detected at higher concentrations.
Low concentrations (ranging from 7.8 to 63 mg/l) of the 75% fucoidan had no effect on PT, but at 125 mg/l, the PT began to increase. The prothrombin ratio [international normalized ratio (INR)] was also affected and it increased but not constantly reflecting the changes in the PT. The AT-III decreased with the fucoidan treatment from 108% for control to 89% at 10 000 mg/l. Interestingly, the 75% fucoidan at high levels (10 000-50 000 mg/l) had a strong effect on anti-Xa assay, whereas at low levels the effect was not obvious. time decreased significantly from 18.62 s at baseline to 17.55 s after 4 days (n ¼ 10, P ¼ 0.04), and in contrast to the in-vivo data AT-III increased significantly from 113.5% at baseline to 117% after 4 days (n ¼ 10, P ¼ 0.02; Table 2 ). We did not look at the thrombin time and AT-III levels after 8 or 12 days of capsules ingestion. For other parameters, PT and prothrombin ratio (INR), nonsignificant changes were noted and antifactor-Xa was not affected under the implemented treatment conditions ( Table 2 ).
In-vivo hemostasis activity of fucoidan
In comparison with the placebo group, there were no significant changes in any of platelet indices when volunteers ingested the 75% fucoidan daily for up to 12 days. 
Detection of plasma level of fucoidan after oral administration
After ingesting the capsules, the median concentration of fucoidan in volunteers' plasma for the placebo group was 0.17 mg/l [confidence interval mean (CIM) 0.02; n ¼ 10], whereas it was 13.06 mg/l (CIM 0.03; n ¼ 10) for the fucoidan-treated group.
Discussion
In this study, orally administered fucoidan prolonged the aPTT from 28.41 s at baseline to 34.01 s after 12 days (n ¼ 10, P ¼ 0.01; average change at 5.6 s), which indicates that fucoidan may alter a specific part of the intrinsic coagulation pathway. The significant changes in thrombin time and AT-III are consistent with this. aPTT may also detect severe functional changes in factors II, V, X, or fibrinogen. It has been widely used to monitor the effectiveness of heparin therapy. Engelberg [13] has shown that there was a small significant effect on aPTT averaged at 2.3 s after administering 20 000 units of oral heparin to 45 humans. Hiebert et al. [14] have also observed in an HIV human trial an increase in the aPTT levels after long-term oral administration of dextran sulfate (8000 Da, 1 g four times daily). These observations are of a similar magnitude to those noted in this study with oral fucoidan. The small increase in aPTT is unlikely to be clinically valuable for acute therapeutic use, but there are implications for possibly including this algal extract in the diet in an ongoing manner.
Orally administered heparin had antithrombotic activity between 50 and 100% in rat models [15] . This was associated with the presence of about 1% of the orally administered heparin dose in plasma. Similarly, our findings indicate that the average level of fucoidan in plasma was 0.3% of the oral dose with plasma levels of about 13.06 mg/l [12] . It is possible that fucoidan has heparin-like action (i.e. to prolong aPTT via anti-Xa and anti-IIa activity).
Circulating levels of factors II, VII, XI, and X are depressed in patients receiving oral anticoagulants [16] . In vivo, there was a nonsignificant increase in the PT. This finding may suggest that fucoidan in the dose used may have little effect on the extrinsic mechanism of coagulation, including no effect on the activity of factors I, II, V, VII, and X. The clinical trial showed no effect of the fucoidan on the anti-Xa assay; however, the in-vitro assay showed that fucoidan at high levels (>10 mg/ml) has an effect on anti-Xa assay. This may suggest that the major mechanism of action is with thrombin rather than factor Xa, which may provide an insight into the mechanism of action of fucoidan.
The in-vitro assays in this study showed that fucoidan has the ability to decrease the AT-III assay in a concentration-dependent manner. The in-vitro thrombin time assay showed that the fucoidan has the ability to alter the last part of the coagulation pathway in a concentrationdependent manner. Prolonging of thrombin time is also seen with heparin therapy and in patients with dysfibrinogenemia or fibrinogenemia. The increase in the thrombin time in vitro may reflect an inhibitory effect on fibrinogenolysis, which is not seen in vivo.
Indeed, the thrombin time, the most sensitive assay to fucoidan in vitro, actually shortened following oral administration. This indicates that fucoidan has the ability to interfere with the final stage of the coagulation process. Fibrinogen levels were not tested in this study however; the results from the in-vitro study may indicate that fucoidan interferes with the fibrin production, thereby preventing the formation of the clot or inhibiting thrombin-mediated conversion of fibrinogen to fibrin. The discordance between the in-vivo and in-vitro results suggests that the circulating material measured as fucoidan might have lacked a significant proportion of its anticoagulant activity.
We did not observe an effect of the fucoidan on blood platelet count, but an effect on platelet aggregation has not been excluded. Studies have shown that fucoidans can enhance platelet aggregation in vitro. However, this effect was found to depend on the fucoidan molecular weight [17] . Another study on baboons found fucoidan to be a potent inhibitor of platelet aggregation in vivo [18] . Platelet function and fibrinolysis have not been assessed in this study.
In conclusion, this study demonstrated that a small quantity of bioavailable fucoidan, given orally, had a modest but significant effect on some of the coagulation assays, in particular, the intrinsic pathway. Changes in the coagulation tests were still within reference ranges and unlikely in themselves to be 'clinically valuable'. However, this study demonstrates the potential of a more bioavailable form of oral fucoidan or for subcutaneous or intravenous forms.
